Table 1 Baseline characteristics of chronic kidney disease progression dataset
Characteristics | Ferritin (ng/mL) | P value | TSAT (%) | P value | ||||
|---|---|---|---|---|---|---|---|---|
Overall, n = 8,995 | ≤ 100, n = 2,450 | > 100, n = 6,545 | Overall, n = 2,440 | ≤ 20, n = 320 | > 20, n = 2,120 | |||
Follow-up, months | 18.2 [6.5, 35.6] | 18.2 [6.3, 35.4] | 18.3 [6.7, 35.6] | 0.879 | 14.9 [4.9, 30.6] | 15.1 [4.5, 31.3] | 14.9 [5.0, 30.5] | 0.905 |
Age, years | 57.0 [44.0, 68.0] | 49.0 [37.0, 64.0] | 59.0 [48.0, 69.0] | < 0.001 | 51.0 [37.0, 64.0] | 49.0 [36.0, 64.0] | 51.0 [37.0, 64.0] | 0.501 |
Sex, female, n (%) | 3,646 (40.5) | 1,574 (64.2) | 2,072 (31.7) | < 0.001 | 1,079 (44.2) | 198 (61.9) | 881 (41.6) | < 0.001 |
Charlson score | 4.0 [2.0, 6.0] | 3.0 [1.0, 5.0] | 4.0 [2.0, 6.0] | < 0.001 | 3.0 [1.0, 4.0] | 2.5 [1.0, 4.0] | 3.0 [1.0, 4.0] | 0.542 |
Laboratory tests | Â | Â | Â | Â | Â | Â | Â | |
Ferritin, ng/mL | 176.2 [93.2, 285.0] | 58.5 [35.4, 78.8] | 231.6 [158.2, 324.0] | < 0.001 | 179.0 [89.5, 286.8] | 106.5 [44.3, 257.5] | 185.7 [96.1, 289.2] | < 0.001 |
TSAT, % | 32.2 [24.6, 41.9] | 27.6 [21.0, 36.3] | 34.0 [26.8, 43.4] | < 0.001 | 31.4 [24.1, 40.2] | 16.5 [13.6, 18.5] | 33.5 [27.3, 42.1] | < 0.001 |
Scr, µmol/L | 84.0 [65.0, 109.0] | 74.0 [58.0, 101.0] | 87.0 [69.0, 111.0] | < 0.001 | 91.0 [73.0, 114.2] | 93.0 [71.0, 118.2] | 91.0 [73.0, 114.0] | 0.744 |
eGFR, ml/min per 1.73m2 | 57.0 [44.0, 68.0] | 49.0 [37.0, 64.0] | 59.0 [48.0, 69.0] | < 0.001 | 51.0 [37.0, 64.0] | 49.0 [36.0, 64.0] | 51.0 [37.0, 64.0] | 0.502 |
Proteinuria, n (%) | Â | Â | Â | Â | Â | Â | Â | Â |
≥ 1+ | 4,867 (54.1) | 1,475 (60.2) | 3,392 (51.8) | < 0.001 | 1,406 (57.6) | 165 (51.6) | 1,241 (58.5) | 0.004 |
Trace | 3,567 (39.7) | 809 (33.0) | 2,758 (42.1) | Â | 937 (38.4) | 133 (41.6) | 804 (37.9) | Â |
NA | 561 (6.2) | 166 (6.8) | 395 (6.0) | Â | 97 (4.0) | 22 (6.9) | 75 (3.5) | Â |
CRP (mg/L), n (%) |  |  |  | < 0.001 |  |  |  | < 0.001 |
≤ 10 | 5,536 (61.5) | 1,679 (68.5) | 3,857 (58.9) |  | 1,900 (77.9) | 198 (61.9) | 1,702 (80.3) |  |
> 10 | 852 (9.5) | 127 (5.2) | 725 (11.1) |  | 219 (9.0) | 76 (23.8) | 143 (6.7) |  |
NA | 2,607 (29.0) | 644 (26.3) | 1,963 (30.0) | Â | 321 (13.2) | 46 (14.4) | 275 (13.0) | Â |
Hb, g/L | 139.0 [132.0, 150.0] | 135.0 [129.0, 145.0] | 141.0 [133.0, 151.0] | < 0.001 | 139.0 [131.0, 149.0] | 133.0 [128.0, 141.0] | 139.0 [132.0, 149.5] | < 0.001 |
TCHO, mmol/L | 4.9 [4.1, 6.0] | 4.9 [4.1, 5.9] | 4.9 [4.1, 6.0] | 0.336 | 5.1 [4.2, 6.2] | 4.9 [4.1, 5.8] | 5.2 [4.3, 6.3] | < 0.001 |
ALB, g/L | 39.9 [35.6, 43.0] | 39.5 [35.2, 42.7] | 40.0 [35.8, 43.2] | < 0.001 | 38.8 [34.4, 42.2] | 38.6 [35.0, 41.4] | 38.8 [34.2, 42.3] | 0.999 |
Comorbidities | Â | Â | Â | Â | Â | Â | Â | Â |
Hypertension, n (%) | 4,335 (48.2) | 1,010 (41.2) | 3,325 (50.8) | < 0.001 | 1,161 (47.6) | 161 (50.3) | 1,000 (47.2) | 0.323 |
Diabetes, n (%) | 2,342 (26.0) | 470 (19.2) | 1,872 (28.6) | < 0.001 | 502 (20.6) | 85 (26.6) | 417 (19.7) | 0.006 |
Cancer, n (%) | 1,094 (12.2) | 316 (12.9) | 778 (11.9) | 0.204 | 231 (9.5) | 29 (9.1) | 202 (9.5) | 0.871 |
Liver disease, n (%) | 2,747 (30.5) | 595 (24.3) | 2,152 (32.9) | < 0.001 | 538 (22.0) | 75 (23.4) | 463 (21.8) | 0.568 |
CVD, n (%) | 2,910 (32.4) | 593 (24.2) | 2,317 (35.4) | < 0.001 | 725 (29.7) | 110 (34.4) | 615 (29.0) | 0.058 |
PVD, n (%) | 2,330 (25.9) | 525 (21.4) | 1,805 (27.6) | < 0.001 | 438 (18.0) | 49 (15.3) | 389 (18.3) | 0.215 |
Infection, n (%) | 852 (9.5) | 172 (7.0) | 680 (10.4) | < 0.001 | 169 (6.9) | 16 (5.0) | 153 (7.2) | 0.181 |
Prescription drugs | Â | Â | Â | Â | Â | Â | Â | Â |
RASi, n (%) | 3,767 (41.9) | 1,029 (42.0) | 2,738 (41.8) | 0.906 | 1,160 (47.5) | 155 (48.4) | 1,005 (47.4) | 0.776 |
Diuretics, n (%) | 1,782 (19.8) | 505 (20.6) | 1,277 (19.5) | 0.256 | 442 (18.1) | 62 (19.4) | 380 (17.9) | 0.582 |
Statins, n (%) | 3,157 (35.1) | 699 (28.5) | 2,458 (37.6) | < 0.001 | 914 (37.5) | 111 (34.7) | 803 (37.9) | 0.300 |
Chemotherapy, n (%) | 870 (9.7) | 236 (9.6) | 634 (9.7) | 0.970 | 202 (8.3) | 34 (10.6) | 168 (7.9) | 0.127 |